MabVax Therapeutics Lines Up $3.7M Ch. 11 Asset Sale - Law360
05/06/19
MabVax Therapeutics Lines Up $3.7M Ch. 11 Asset Sale Law360
After a last-minute negotiating flurry, biotech firm MabVax Therapeutics Holdings secured tentative approval Monday for the $3.7 million sale of many of its ...
[more]